Unveiling 5 Analyst Insights On IDEAYA Biosciences


In the preceding three months, 5 analysts have released ratings for IDEAYA Biosciences IDYA, presenting a wide array of perspectives from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 2 3 0 0 0
Last 30D 0 1 0 0 0
1M Ago 0 0 0 0 0
2M Ago 1 0 0 0 0
3M Ago 1 2 0 0 0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $55.4, a high estimate of $60.00, and a low estimate of $52.00. This current average has increased by 24.02% from the previous average price target of $44.67.

Understanding Analyst Ratings: A Comprehensive Breakdown

The analysis of recent analyst actions sheds light on the perception of IDEAYA Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Robert Driscoll Wedbush Maintains Outperform $52.00 -
Yigal Nochomovitz Citigroup Raises Buy $60.00 $40.00
Justin Zelin BTIG Announces Buy $55.00 -
Anupam Rama JP Morgan Raises Overweight $57.00 $51.00
Gregory Renza RBC Capital Raises Outperform $53.00 $43.00

Key Insights:

  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to IDEAYA Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of IDEAYA Biosciences compared to the broader market.
  • Price Targets: Analysts predict movements in price targets, offering estimates for IDEAYA Biosciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into IDEAYA Biosciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on IDEAYA Biosciences analyst ratings.

Unveiling the Story Behind IDEAYA Biosciences

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.

IDEAYA Biosciences's Economic Impact: An Analysis

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: IDEAYA Biosciences's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -2.49%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: IDEAYA Biosciences's net margin is impressive, surpassing industry averages. With a net margin of -865.76%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): IDEAYA Biosciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -6.01%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): IDEAYA Biosciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.74%, the company may face hurdles in achieving optimal financial performance.

Debt Management: IDEAYA Biosciences's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.

How Are Analyst Ratings Determined?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!